Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279449 | 0.98 | RXRB (0.42) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL31468782 | 0.93 | TRPA1 (0.36) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL3453086 | 0.82 | HPGD (0.40) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL3452332 | 0.80 | RXRB (0.41) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL9720050 | 0.80 | TSHR (0.46) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL81619 | 0.77 | RXRB (0.39) | HPGDCYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL2990486 | 0.76 | TSHR (0.42) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL2633408 | 0.76 | GRIN2B (0.46) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL695095 | 0.76 | TSHR (0.42) | TSHRHPGDCYP1A2MAPTCYP2C9 | |
| SCHEMBL5504129 | 0.76 | KMT2A (0.47) | TSHRMAPTRXRBADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676915-A1 | SORTILINE MODULATORS | Vesper Bio Aps (DK) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184471-A1 | SORTILINE MODULATORS | VESPER BIO APS (DK) | 2024-09-12 | — | — | WO | disclosed |
| EP-4428122-A1 | SORTILINE MODULATORS | Vesper Bio Aps (DK) | 2024-09-11 | — | — | EP | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022117059-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | 瑞石生物医药有限公司 | 2022-06-09 | — | — | WO | disclosed |
| CN-107531613-B | Benzo-aliphatic ring-substituted alkylamine compound and application thereof | 华东理工大学 | 2021-02-05 | — | — | CN | disclosed |
| WO-2017132912-A1 | ALKYLAMINE WITH BENZOALICYCLIC SUBSTITUENT AND APPLICATION THEREOF | 华东理工大学 | 2017-08-10 | — | — | WO | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061760-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| EP-1558601-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004037811-A1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | TSHR 3921/4885HPGD 3675/4885CYP1A2 4862/4885 |
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | TSHR 599/4885HPGD 1059/4885CYP1A2 1977/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | TSHR 599/4885HPGD 1059/4885CYP1A2 1977/4885 |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | TSHR 3393/4885HPGD 279/4885CYP1A2 101/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | TSHR 1003/4885HPGD 990/4885CYP1A2 2212/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | TSHR 3163/4885HPGD 542/4885CYP1A2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.